Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial

by Veenstra-VanderWeele, Jeremy, Cook, Edwin H, King, Bryan H, Zarevics, Peter, Cherubini, Maryann, Walton-Bowen, Karen, Bear, Mark, Wang, Paul P, Carpenter, Randall L
Published 2020

Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial

by Berry-Kravis, Elizabeth M., Hessl, David, Rathmell, Barbara, Zarevics, Peter, Cherubini, Maryann, Walton-Bowen, Karen, Mu, Yi, Nguyen, Danh V., Gonzalez-Heydrich, Joseph, Wang, Paul P., Carpenter, Randall L., Hagerman, Randi J., Bear, Mark
Published 2015

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

by Erickson, Craig A., Veenstra-Vanderweele, Jeremy M., Melmed, Raun D., McCracken, James T., Ginsberg, Lawrence D., Sikich, Linmarie, Scahill, Lawrence, Cherubini, Maryann, Zarevics, Peter, Walton-Bowen, Karen, Carpenter, Randall L., Wang, Paul P., King, Bryan H., Bear, Mark
Published 2015

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

by Berry-Kravis, Elizabeth M., Lindemann, Lothar, Jønch, Aia E., Apostol, George, Bear, Mark, Carpenter, Randall L, Crawley, Jacqueline N., Curie, Aurore, Des Portes, Vincent, Hossain, Farah, Gasparini, Fabrizio, Gomez-Mancilla, Baltazar, Hessl, David, Loth, Eva, Scharf, Sebastian H., Wang, Paul P., Von Raison, Florian, Hagerman, Randi, Spooren, Will, Jacquemont, Sébastien
Published 2020